Scientific References Check out the scientific literature that supports our molecular targets and our synthetic lethal approach. February 2025 A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma Isabel Soria-Bretones, Matias Casas-Selves, Et Al. bioRxiv October 2024 Individualized schedule improves rates and severity of anemia in patients treated with lunresertib, a PKMYT1 inhibitor, and camonsertib, an ATR inhibitor, in the Phase I MYTHIC study Højgaard Et Al. ENA 2024 September 2024 Genotypically-selected pan cancer trial of camonsertib with palliative radiation in the treatment of metastatic tumors harboring an ataxia-telangiectasia mutated (ATM) mutation Nancy Lee, Et Al. ASTRO 2024 September 2024 Driver alterations in FBXW7, PPP2R1A, CCNE1 confer a poor prognosis in patients with metastatic gynecologic cancers Alison M. Schram, Et Al. AACR Ovarian Research Symposium 2024 September 2024 Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF) Benedito A. Carneiro, Et Al. ESMO Congress 2024 August 2024 Low Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer Mi Li, Et Al. Cancer Research, August 26 2024 June 2024 Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study) Zev A Wainberg, Et Al. ESMO Gastrointestinal Cancers Annual Congress 2024 - Abstract 504MO June 2024 Characterizing intra-tumoral heterogeneity of CCNE1 amplification in ovarian cancer using digital pathology Adam Petrone, Isabel Soria-Bretones, Adrienne Johnson, Et Al. AACR SPECIAL CONFERENCE IN CANCER RESEARCH: EXPANDING AND TRANSLATING CANCER SYNTHETIC VULNERABILITIES May 2024 Identification and Biosynthesis of an N-Glucuronide Metabolite of Camonsertib Robert Papp, Laird Trimble, Adrian J. Fretland, et al. Drug Metabolism and Disposition May 2024 ATR inhibitor, camonsertib, dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study) Elisa Fontana, MD, PhD, Ezra Rosen, MD, PhD, et al. Journal of the National Cancer Institute 12345 We have a number of synthetic lethal therapies in development. View Pipeline
